Spectrum Pharmaceuticals Company Profile (NASDAQ:SPPI)

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its earnings results on Tuesday, May, 2nd. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.02. The business earned $29.10 million during the quarter, compared to analyst estimates of $32.23 million. Spectrum Pharmaceuticals had a negative net margin of 62.39% and a negative return on equity of 24.06%. View Spectrum Pharmaceuticals' Earnings History.

4 equities research analysts have issued 1 year target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $9.00 to $11.00. On average, they expect Spectrum Pharmaceuticals' stock price to reach $10.00 in the next year. View Analyst Ratings for Spectrum Pharmaceuticals.

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Spectrum focuses in the fields of hematology and oncology. The company's progress with its lead pipeline candidate Rolontis has been quite impressive. However, Spectrum’s efforts to gain approval for Qapzola (bladder cancer) in the U.S. suffered a setback with the FDA issuing a complete response letter (CRL) in Nov 2016. Additional issues on the regulatory/development front could affect the stock adversely. Also, low product sales remain a cause of concern. On the flip side, with the company entering into out-licensing agreements for a number of products, it will now be able to focus on Evomela and the development of its pipeline candidates. Spectrum’s shares outperformed the Medical Drugs industry so far this year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/5/2017)
• 2. Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)

Some companies that are related to Spectrum Pharmaceuticals include Global Blood Therapeutics (GBT), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Genus plc (GNS), Immunomedics (IMMU), Cellectis S.A. (CLLS), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Albany Molecular Research (AMRI), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA), Enanta Pharmaceuticals (ENTA), CRISPR THERAPTC (CRSP), Editas Medicine (EDIT), Mesoblast Limited (MESO) and Intellia Therapeutics (NTLA).

Spectrum Pharmaceuticals' management team includes the folowing people:

• Rajesh C. Shrotriya M.D., Chairman of the Board, Chief Executive Officer
• Joseph W. Turgeon, President, Chief Operating Officer
• Kurt A. Gustafson, Chief Financial Officer, Executive Vice President
• Luigi Lenaz M.D., Lead Independent Director
• Gilles R. Gagnon, Director
• Raymond Wayne Cohen, Independent Director
• Stuart M. Krassner, Independent Director
• Anthony E. Maida III, Ph.D., Independent Director

Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.14%), Louisiana State Employees Retirement System (0.04%), Capstone Asset Management Co. (0.02%) and State of Alaska Department of Revenue (0.02%). View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Capstone Asset Management Co. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Bank of Montreal Can. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $8.02.